Biohaven Pharmaceutical (NYSE:BHVN) had its price objective boosted by analysts at Leerink Swann from $62.00 to $64.00 in a report issued on Friday, The Fly reports. The firm currently has an “outperform” rating on the stock. Leerink Swann’s target price points to a potential upside of 16.68% from the stock’s previous close.
A number of other brokerages have also recently issued reports on BHVN. Zacks Investment Research cut shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday, October 21st. Cantor Fitzgerald raised their target price on Biohaven Pharmaceutical from $87.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, October 28th. ValuEngine cut Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Goldman Sachs Group set a $89.00 price target on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Finally, Morgan Stanley set a $50.00 price target on Biohaven Pharmaceutical and gave the stock a “hold” rating in a research note on Friday, August 9th. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $71.42.
BHVN stock opened at $54.85 on Friday. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -8.92 and a beta of 0.46. Biohaven Pharmaceutical has a 12 month low of $29.17 and a 12 month high of $67.86. The firm has a 50 day moving average of $50.24 and a two-hundred day moving average of $47.00.
In related news, insider Elyse Stock sold 17,700 shares of Biohaven Pharmaceutical stock in a transaction on Friday, October 18th. The shares were sold at an average price of $45.07, for a total value of $797,739.00. Following the transaction, the insider now owns 17,700 shares in the company, valued at approximately $797,739. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Eric Aguiar sold 1,250 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $55.24, for a total transaction of $69,050.00. Following the transaction, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $662,880. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,414 shares of company stock valued at $1,912,724. 23.90% of the stock is owned by insiders.
Large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in shares of Biohaven Pharmaceutical by 511.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock worth $46,000 after purchasing an additional 920 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in Biohaven Pharmaceutical in the 2nd quarter worth approximately $65,000. Aperio Group LLC bought a new position in Biohaven Pharmaceutical in the 2nd quarter worth approximately $71,000. Glen Harbor Capital Management LLC lifted its holdings in shares of Biohaven Pharmaceutical by 165.9% during the second quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock worth $76,000 after buying an additional 1,088 shares during the last quarter. Finally, Canton Hathaway LLC acquired a new position in shares of Biohaven Pharmaceutical during the third quarter worth approximately $83,000. 93.52% of the stock is currently owned by institutional investors.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Further Reading: What is a stock portfolio tracker?
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.